GET DAILY SIGNALSIBEX Limited (IBEX) Reports Record Revenue and Raises Full-Year Guidance After Solid First Quarter
Key Takeaways
- Revenue rose 16% year over year to a record $175.2 million, marking a seventh consecutive quarter of double-digit organic growth.
- GAAP diluted earnings per share (EPS) increased 20% to $0.99, while adjusted diluted EPS climbed 21% to $1.10, ahead of analyst expectations.
- Adjusted EBITDA rose 29% to $25.2 million, with margin expanding to 14.4% from 12.9%.
- Management raised full-year fiscal 2027 guidance, now projecting revenue of $720–$735 million and adjusted EBITDA of $96–$99 million.
- Gross margin widened 90 basis points to 30.4%, helped by growth in higher-margin onshore and HealthTech revenue.
Earnings Context and Why It Matters
IBEX Limited (IBEX), a global provider of outsourced business services and AI-powered customer experience solutions, entered fiscal 2027 on a strong trajectory after delivering more than 15% full-year revenue growth in fiscal 2026. This quarterly report served as an important check on whether that momentum could continue and whether the company could keep expanding margins while scaling its higher-value AI and digital acquisition offerings. For investors, the results carried added weight because management used the update to reset full-year guidance, providing a clearer view on demand across health technology, travel, retail, and technology verticals in a competitive business process outsourcing landscape. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the first quarter of fiscal 2027, ended September 30, 2026, IBEX Limited (IBEX) reported revenue of $175.2 million, up 16% from $151.2 million in the prior-year period and above the company’s own guidance range of $168–$170 million. Growth was led by a 40% increase in HealthTech, alongside gains in travel, transportation and logistics, technology, and retail and e-commerce.
GAAP net income increased to $14.8 million from $12.0 million a year earlier, with diluted EPS of $0.99 versus $0.82. On an adjusted basis, net income rose to $16.4 million from $13.1 million, and adjusted diluted EPS increased 21% to $1.10, exceeding consensus estimates. Adjusted EBITDA climbed 29% to $25.2 million, with margin improving 150 basis points to 14.4%.
Operating cash flow reached a first-quarter record of $16.3 million, and free cash flow was $9.2 million. The company ended the period with net cash of $35.0 million and repurchased 122,806 shares for $4.4 million. Management raised fiscal 2027 guidance, now expecting revenue of $720–$735 million and adjusted EBITDA of $96–$99 million, with capital expenditures of roughly $30 million.
Market Reaction and Investor Sentiment
The market responded positively to the release. IBEX Limited (IBEX) shares, which closed regular trading up modestly at $44.84, gained more than 8% in after-hours trading on November 5, 2026, according to market data, reflecting investor approval of the record results and the raised full-year outlook. The beat versus guidance and consensus EPS, combined with meaningful margin expansion, appeared to reinforce confidence in the company’s strategy of shifting its revenue mix toward higher-margin onshore, HealthTech, and AI-driven services. Sentiment remains supportive, though analysts’ average rating holds at “Hold” with a 12-month price target below the post-earnings share price, suggesting the market has already priced in much of the near-term momentum.
Forward Outlook and Key Factors to Monitor
Following the raised guidance, investors will be watching whether IBEX Limited (IBEX) can sustain its double-digit organic growth while continuing to expand margins through fiscal 2027. The company’s ability to convert its AI agent solutions and digital acquisition business into durable, higher-margin revenue remains a central theme, as does the pace of new client wins and expansion within its existing embedded base.
Cost and margin dynamics also warrant attention. Management has guided to a full-year effective tax rate of roughly 21–22% before discrete items, up from the prior-year quarter’s 11%, which could temper net income growth even as operating performance strengthens. Capacity investments—guided at about $30 million in capital expenditures for the year—will be another variable to track, since expansion is concentrated in the company’s highest-margin offshore regions.
Finally, industry conditions matter. The broader customer experience and BPO sector faces ongoing pricing pressure as AI automation reshapes traditional outsourcing, and IBEX’s positioning as an AI-powered provider will be tested against larger competitors. Sustained HealthTech growth, client diversification, and free cash flow generation are the key indicators investors should monitor in the quarters ahead.
Refining Research with Tickeron’s AI Screener
In my research process, I often turn to Tickeron’s AI Screener to filter stocks based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. It helps me quickly scan thousands of names, compare peers in the BPO space, and refine my watchlist when evaluating opportunities like IBEX Limited. This approach adds efficiency when monitoring shifting market conditions around earnings releases and guidance updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for IBEX turns negative, indicating new downward trend
IBEX saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In 73 of the 91 cases, the stock moved further down in the following days. The odds of a decline are at 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for IBEX moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 21 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Moving Average Convergence Divergence Histogram (MACD) for IBEX turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 34 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBEX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
IBEX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBEX advanced for three days, in 251 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 167 of 213 cases where IBEX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 27 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. IBEX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.354) is normal, around the industry mean (2.990). P/E Ratio (12.464) is within average values for comparable stocks, (18.323). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.284). Dividend Yield (0.000) settles around the average of (0.205) among similar stocks. P/S Ratio (0.926) is also within normal values, averaging (139.965).
The Tickeron PE Growth Rating for this company is 70 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in technology-enabled customer lifecycle experience solutions
Industry InformationTechnologyServices
Advertisement